Clinical significance of macrophage heterogeneity in human malignant tumors

Cancer Science

Volumn 105, Issue 1, 2014, Pages 1-8

  Komohara, Yoshihiro ^a   Jinushi, Masahisa ^b   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cancer; CD163; M2; Macrophage; TAM

Indexed keywords

CD163 ANTIGEN; PROTEIN M2;

ANGIOGENESIS; CANCER THERAPY; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; DENDRITIC CELL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

CANCER; CD163; M2; MACROPHAGE; TAM;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; DISEASE PROGRESSION; HUMANS; MACROPHAGES; NEOPLASMS;

EID: 84892865013     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12314     Document Type: Review

References (106)

1. Monis B, Weinberg T. Cytochemical study of esterase activity of human neoplasms and stromal macrophages. Cancer 1961; 14: 369-77.
2. Underwood JC, Carr I. The ultrastructure of the lymphoreticular cells in non-lymphoid human neoplasms. Virchows Arch B Cell Pathol 1972; 12: 39-50.
3. Lauder I, Aherne W, Stewart J, Sainsbury R. Macrophage infiltration of breast tumours: a prospective study. J Clin Pathol 1977; 30: 563-8.
4. Kreutz M, Fritsche J, Andreesen R. Macrophages in tumor biology. In; Burke B, Lewis CE, eds. The Macrophage, 2nd edn. Oxford, UK: Oxford Univ. Press, 2002; 458-89.
5. Tagliabue A, Mantovani A, Kilgallen M, Herberman RB, McCoy JL. Natural cytotoxicity of mouse monocytes and macrophages. J Immunol 1979; 122: 2363-70.
6. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
7. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-65.
8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8.
9. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011; 9: 216.
10. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
11. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-27.
12. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
13. Brown CE, Vishwanath RP, Aguilar B et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007; 179: 3332-41.
14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
15. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84: 623-30.
16. Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS ONE 2011; 6: e23902.
17. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102: 522-8.
18. Hernandez L, Smirnova T, Kedrin D et al. The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12. Cancer Res 2009; 69: 3221-7.
19. Kubota Y, Takubo K, Shimizu T et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med 2009; 206: 1089-102.
20. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193: 727-40.
21. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86: 1065-73.
22. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol 2011; 2011: 565187.
23. Maru Y. Logical structures extracted from metastasis experiments. Cancer Sci 2009; 100: 2006-13.
24. Hiratsuka S, Watanabe A, Sakurai Y et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10: 1349-55.
25. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-75.
26. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
27. Goerdt S, Orfanos CE. Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 1999; 10: 137-42.
28. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
29. Komohara Y, Hirahara J, Horikawa T et al. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006; 54: 763-71.
30. Tomokiyo R, Jinnouchi K, Honda M et al. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis 2002; 161: 123-32.
31. Komohara Y, Takemura K, Lei XF et al. Delayed growth of EL4 lymphoma in SR-A-deficient mice is due to upregulation of nitric oxide and interferon-gamma production by tumor-associated macrophages. Cancer Sci 2009; 100: 2160-6.
32. Neyen C, Pluddemann A, Mukhopadhyay S et al. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol 2013; 190: 3798-805.
33. Yu X, Wang XY. Antagonizing the innate pattern recognition receptor CD204 to improve dendritic cell-targeted cancer immunotherapy. Oncoimmunology 2012; 1: 770-2.
34. Komohara Y, Hasita H, Ohnishi K et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011; 102: 1424-31.
35. Niino D, Komohara Y, Murayama T et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 2010; 60: 278-83.
36. Komohara Y, Niino D, Saito Y et al. Clinical significance of CD163 tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 945-51.
37. Shigeoka M, Urakawa N, Nakamura T et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci 2013; 104: 112-8.
38. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
39. Umemura N, Saio M, Suwa T et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008; 83: 1136-44.
40. Ino Y, Yamazaki-Itoh R, Shimada K et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013; 108: 914-23.
41. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 2010; 10: 117-26.
42. Lee H, Deng J, Kujawski M et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16: 1421-8.
43. Komohara Y, Horlad H, Ohnishi K et al. Importance of direct macrophage - Tumor cell interaction on progression of human glioma. Cancer Sci 2012; 103: 2165-72.
44. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-95.
45. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27: 2383-92.
46. Jinushi M, Chiba S, Yoshiyama H et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA 2011; 108: 12425-30.
47. Bao S, Tang F, Li X et al. Epigenetic reversion of post-implantation epiblast to pluripotent embryonic stem cells. Nature 2009; 461: 1292-5.
48. Rao G, Wang H, Li B et al. Reciprocal interactions between tumor-associated macrophages and CD44-positive cancer cells via osteopontin/CD44 promote tumorigenicity in colorectal cancer. Clin Cancer Res 2013; 19: 785-97.
49. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802-7.
50. Ueha S, Shand FH, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol 2011; 11: 783-8.
51. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
52. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40: 2969-75.
53. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
54. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18: 5212-23.
55. MacDonald KP, Munster DJ, Clark GJ et al. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512-20.
56. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13: 1145-56.
57. Jongbloed SL, Kassianos AJ, McDonald KJ et al. Human CD141+(BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207: 1247-60.
58. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+ FXIIIA+ macrophages. J Clin Invest 2007; 117: 2517-25.
59. Pello OM, De Pizzol M, Mirolo M et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012; 119: 411-21.
60. Satoh T, Takeuchi O, Vandenbon A et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010; 11: 936-44.
61. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011; 11: 750-61.
62. Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23: 249-62.
63. Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011; 9: 177.
64. Qian BZ, Li J, Zhang H et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
65. Roland CL, Dineen SP, Lynn KD et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009; 8: 1761-71.
66. Fujiwara Y, Komohara Y, Ikeda T, Takeya M. Corosolic acid inhibits glioblastoma cell proliferation by suppressing the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B in tumor cells and tumor-associated macrophages. Cancer Sci 2011; 102: 206-11.
67. Horlad H, Fujiwara Y, Takemura K et al. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells. Mol Nutr Food Res 2013; 57: 1046-54.
68. Wang B, Xu D, Yu X et al. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. Ann Surg Oncol 2011; 18: 2585-93.
69. Ohno S, Ohno Y, Suzuki N et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004; 24: 3335-42.
70. Soeda S, Nakamura N, Ozeki T et al. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 2008; 109: 122-8.
71. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13: 1472-9.
72. Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S. Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2004; 99: 1667-74.
73. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857-61.
74. Zhu XD, Zhang JB, Zhuang PY et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008; 26: 2707-16.
75. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 2012; 65: 159-63.
76. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996; 56: 4625-9.
77. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15: 1069-74.
78. Kawahara A, Hattori S, Akiba J et al. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Oncol Rep 2010; 24: 405-15.
79. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000; 7: 263-9.
80. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011; 117: 5234-44.
81. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42: 1414-21.
82. Asgharzadeh S, Salo JA, Ji L et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012; 30: 3525-32.
83. Fujiwara T, Fukushi J, Yamamoto S et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011; 179: 1157-70.
84. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-85.
85. Canioni D, Salles G, Mounier N et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26: 440-6.
86. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med 2007; 5: 62.
87. Mano Y, Aishima S, Fujita N et al. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. Pathobiology 2013; 80: 146-54.
88. Kong LQ, Zhu XD, Xu HX et al. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS ONE 2013; 8: e59771.
89. Hasita H, Komohara Y, Okabe H et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 2011; 101: 1913-9.
90. Kurahara H, Shinchi H, Mataki Y et al. Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer. J Surg Res 2009; 167: e211-9.
91. Yoshikawa K, Mitsunaga S, Kinoshita T et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012; 103: 2012-20.
92. Chung FT, Lee KY, Wang CW et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 2012; 131: E227-35.
93. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS ONE 2011; 6: e21874.
94. Hirayama S, Ishii G, Nagai K et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol 2012; 7: 1790-7.
95. Fujii N, Shomori K, Shiomi T et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 2012; 41: 444-51.
96. Reinartz S, Schumann T, Finkernagel F et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 2014; 134: 32-42.
97. Buddingh EP, Kuijjer ML, Duim RA et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011; 17: 2110-9.
98. Espinosa I, Beck AH, Lee CH et al. Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol 2009; 174: 2347-56.
99. Jensen TO, Schmidt H, Moller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27: 3330-7.
100. Bronkhorst IH, Ly LV, Jordanova ES et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011; 52: 643-50.
101. Wada N, Zaki MA, Hori Y et al. Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 2012; 60: 313-9.
102. Zaki MA, Wada N, Ikeda J et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011; 459: 361-6.
103. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012; 97: 1080-4.
104. Tan KL, Scott DW, Hong F et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012; 120: 3280-7.
105. Clear AJ, Lee AM, Calaminci M et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood 2010; 115: 5053-6.
106. Suyani E, Sucak GT, Akyurek N et al. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol 2013; 92: 669-77.